KD014
KD014 (DX-2400) is a human monoclonal antibody (mAb) targeting MMP14 (Ki: 0.9 nM) . KD014 inhibits TGFβ and SMAD2/3 activity, increases macrophage numbers and iNOS expression, and shifts macrophage phenotype toward anti-tumor M1-like. KD014 has anti-tumor activity in three different tumor models (MDA-MB-231, MDA-MB-435, and PC3) . KD014 can be used in breast cancer research[1][2].
Product Specifications
Product Name Alternative
DX-2400; DX-2410
UNSPSC
12352203
Target
MMP; NO Synthase; TGF-beta/Smad; TGF-β Receptor
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
96.98
Molecular Weight
(144.01 kDa)
References & Citations
[1]Ager EI, et al. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst. 2015 Feb 20;107 (4) :djv017.|[2]Devy L, et al. Antitumor efficacy of DX-2400, a potent and selective human antibody MMP-14 inhibitor discovered using phage display technology[J]. Cancer Research, 2007, 67 (9_Supplement) : 5618-5618.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
MMP-14
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
353022 100 µg
RING2 (BAP1, DING, HIPI3, RING1B, DinG, Ring1b, HIP2 Interacting Protein 3, RING Finger Protein BAP1, RNF2)
Sign In for Pricing
View Details 